Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
By E. Yeh, Ann T. Tong, D. Lenihan, S. Yusuf, J. Swafford, Christopher J. Champion, J. Durand, H. Gibbs, A. A. Zafarmand, M. Ewer and 1 more. Circulation, 2004
840 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/1d180888e7bd0c1381741865fb4cf4586ee76093
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Greenfield
- E. Stovall
- A. Dey
- Arvind K. Singh Chandel
- Rupa Sanyal
- Amarnath Mishra
- D. Pandey
- V. De Falco
Citations in the corpus
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials (2010, background): “However, these tend to have a very broad scope and cover many different agents and tend to be opinion pieces which may be biased in their selection and presentation of study results [5,9-11].”
- From cancer patient to cancer survivor : lost in transition (2006, background): “Other chemotherapies can cause long-term heart problems: alkylating agents (e.g., cisplatin) can cause ischemia, hypertension, and congestive heart failure; trastuzumab (Herceptin) can cause myocardial depression;21 and paclitaxel (Taxol) is associated with arrhythmias (Yeh et al., 2004).”
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, unknown): “2-fold higher rate of cardiac death compared with the age-matched and sex-matched national average.(18,19) Compared with controls, long-term childhood cancer survivors had 15-fold increased rates of congestive HF, 10-fold higher rates of CVD, and 9-fold higher rates of stroke.”
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Different classes of chemotherapeutic drugs have varying impacts on cardiac cells, leading to multiple types of systemic conditions adversely affecting patients’ survival.(166) Loss of libido and sexual dysfunctions are other conditions caused due to long-term exposure to these drugs, which affects ”